Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB011 (hgd40) in mild to moderate atopic dermatitis
NCT02079688Phase 2Completed
- Sponsor
- sterna biologicals
- Start
- Feb 2014
- Primary completion
- Nov 2016
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing SB011 (hgd40) with Vehicle (2 arms). Primary endpoint: Change of local SCORing atopic dermatitis from baseline to Day 15. Started Feb 2014; status: completed.
02
Drugs
SB010
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT02079688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02079688.